Skip to main content

Table 3 Adjusted estimates of risk reduction of the onset of each deterioration assessment for patients taking enzalutamide vs. placebo (inverted hazard ratios [HR] and 95% confidence intervals [CI])

From: Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial

Deterioration events

Adjusted 1/HR

95% CI

P value

Any worsening from baseline full health (EQ index = 1)

0.52

0.42–0.65

<0.0001

Any decrease in EQ-5D index

0.53

0.48–0.61

<0.0001

Any decrease in EQ-5D VAS

0.62

0.55–0.70

<0.0001

“Worsening” on PCHC

0.76

0.65–0.88

0.0003

Worsening in EQ-5D dimensions

 Mobility

0.87

0.68–1.10

0.2357

 Self-care

0.60

0.43–0.83

0.0019

 Usual Activities

0.85

0.70–1.03

0.1066

 Pain/Discomfort

0.57

0.47–0.68

<0.0001

 Anxiety/Depression

0.66

0.53–0.83

0.0003

  1. PCHC Paretian Classification of Health Change, VAS visual analogue scale
  2. Relative risk reduction and 95% CIs from Cox proportional hazards models adjusted by the following baseline factors: age, fatigue score, pain score, geographic region, and baseline EQ-5D index or corresponding dimension value
Back to article page

Health and Quality of Life Outcomes

ISSN: 1477-7525

Contact us